Hsbc


ECB’s antifragmentation tool

28/06/22 -"The ECB’s antifragmentation tool will have to overcome several obstacles to be agreed upon. According to some press articles, the ECB will propose to sterilise the central bank reserves issued ..."

Pages
59
Language
English
Published on
28/06/22
You may also be interested by these reports :
21/08/26
In our previous paper on Handelsbanken (SELL; Sweden), we pointed out that the bank was suffering from its “Swedishness”, with the bank’s dependence ...

12/08/26
ABN delivered a strong, high-quality Q2, beating consensus by 5% on revenue across NII, fees and costs, with RoE at 12.1%. FY26 NII (c. €6.6bn) and ...

10/08/26
The recent turmoil in EFG International’s (ADD, Switzerland) share price stems from concerns regarding the bank’s ability to keep its margins under ...

07/08/26
As announced in our post-release comments, we have made only minor changes to our forecasts. This has had a limited impact on the overall valuation. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO